

# Oncology Markets for Tyrosine Kinase Inhibitors

Therapeutics, Markets, Products,  
Strategies and Forecasts

Report Brochure




Greystone  
Research Associates

Greystone Research Associates is pleased to announce the publication of a new market assessment. **Oncology Markets for Tyrosine Kinase Inhibitors** is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug developers, and healthcare marketers with a detailed understanding of the economics, technologies, indications, and commercial opportunities for oncology drugs that target specific cancers. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

## Precision Therapeutics

As a whole, tyrosine kinases phosphorylate specific amino acids on substrate enzymes, which subsequently alter signal transduction leading to downstream changes in cellular biology. The downstream signal transduction set off by TKs can modify cell growth, migration, differentiation, apoptosis, and death. Numerous targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. Their approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of cancer. This report examines the three dozen therapeutic drugs and their therapeutic MOA.

### Report Value Matrix




# Table of Contents


- Executive Summary
- Biological Drug Market Dynamics
- Targeted Oncology
- Tyrosine Kinase Inhibitors
- Breast Cancers
  - TKI Therapeutics - Breast Cancer (Two Approved TKIs)
  - Breast Cancers - Clinical Trial Activity
  - Breast Cancers – Market Data
- Gastrointestinal Cancers
  - Gastric Cancer
  - Gastrointestinal Carcinoid Tumors
  - Gastrointestinal Stromal Tumors
  - TKI Therapeutics - Gastrointestinal Cancers (Three Approved TKIs)
- Hematology Cancers
  - Acute Lymphoblastic Leukemia
  - Acute Myeloid Leukemia
  - Chronic Lymphocytic Leukemia
  - Chronic Myelogenous Leukemia
  - TKI Therapeutics – Hematology Cancers
  - TKI Clinical Trial Activity - Hematology Cancers (Seven Approved TKIs)
- Leukemias
- Lymphomas
- Myeloma
- Hematology Cancers - Market Data
- Lung Cancers
  - Non-small Cell Lung Cancer
  - Small Cell Lung Cancer
  - TKI Therapeutics – Lung Cancers (Thirteen Approved TKIs)
  - Clinical Trial Activity – Lung Cancers
  - Market Data
- Melanoma
  - TKI Therapeutics – Melanoma (Three Approved TKIs)
  - Melanoma - Clinical Trial Activity
  - Melanoma - Market Data
- Renal Cell Carcinoma
  - TKI Therapeutics – Renal Cell Carcinoma (Three Approved TKIs)
  - Renal Cell Carcinoma - Clinical Trial Activity
  - Renal Cell Carcinoma - Market Data
- Thyroid Cancers
  - TKI Therapeutics - Thyroid Cancers (Five Approved TKIs)
  - Thyroid Cancers - Market Data

# Numerous Charts, Tables & Visualizations

Metastatic Gastric Cancer, Active Clinical Trials, clinicaltrials.gov (2/6/2020)  
(number of trials by first-listed intervention)  
Minimum Two Active Trials




Metastatic Gastric Cancer, Active Clinical Trials, clinicaltrials.gov (2/6/2020)  
(number of trials by trial phase (total number of trials))





Metastatic Gastric Cancer, Active Clinical Trials (number of trials by lead trial sponsor/collab)  
Minimum Two Active Trials



Lung Cancers - Important mAb Therapeutic Drugs  
(Sphere size indicates relative revenue for all approved oncology indications)



AMGEN Oncology mAb Product Revenue



Amgen - Approved Oncology Biologicals by Indication


DrugName	Breast Cancers	Cervical Cancer	Colorectal Cancers	Hematology Cancers	Lung Cancers	Metastatic Gastric Cancer	Neurological Cancers	Renal Cell Carcinomas
BLINCYTO				●				
KANJINTI	●					●		
IMVASI		●	●		●		●	●
VECTIBIX			●					

# Clear & Concise Market Segment Data


Oncology mAbs, Competitive Considerations – FDA/EMA Approved Product Market Coverage by Supplier

(Commercial availability may vary due to launch delays related to patent litigation)

Supplier (group)	Breast Cancers	Cervical Cancer	Colorectal Cancers	Gastric Cancer	Granulomatosis	Hematology Cancers	Lung Cancers	Melanomas	Metastatic Gastric Cancer	Mycosis Fungoidis	Neurological Cancers	Renal Cell Carcinomas	Reproductive Cancer	Rheumatoid Arthritis	SCC of the Head and Neck	Skin Cancers	Soft Tissue Sarcoma	Urothelial Cancers
AMGEN	●	●	●			●	●		●		●	●						
ASTELLAS																		●
ASTRAZENECA						●	●											●
BRISTOL MYERS SQUIBB			●			●	●	●				●						
CELLTRION INC	●					●												
DAIICHI SANKYO	●																	
ELI LILLY AND CO			●	●			●										●	
EMD SERONO INC												●				●		●
GENENTECH	●	●	●		●	●	●		●		●	●	●	●				●
GENZYME																		
GLAXO GRP LTD																		
IMCLONE			●															
JANSSEN BIOTECH																		
KYOWA KIRIN																		
MERCK SHARP DOHME																		
MYLAN GMBH	●																	
PFIZER INC	●	●	●															
REGENERON PHARMACEUT...																		
SAMSUNG BIOEPI S CO LTD	●																	
SPECTRUM PHARMS																		
UNITED THERAP																		
WYETH PHARMS INC																		



SupplierActivityMap



## What You Will Learn

- What is the market share of approved TKI therapeutics?
- What is the global supply picture for targeted TKI therapeutics?
- Who are the market leaders, by Indication? by Product?
- What is the therapeutic TKI coverage across all oncology indications?
- What are the established products in this space? by target, indication, API class, revenue?
- What is the competitive TKI picture for the major Oncology market segments?
- Drug treatment resources
- Competitive therapy map
- Clinical trial activity
- Who are the leading competitors in the field of next-generation TKI therapeutics?

## Report Format and Availability

This report is available electronic format. A site license for a single physical location and a corporate license are also available. Custom licensing options to address specific company user requirements are available by calling client services at 603-440-5710, or by emailing [clientservices@greystoneassociates.org](mailto:clientservices@greystoneassociates.org).

## Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

## About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

## Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address and billing address.

### Payment

We accept the following forms of payment:

**Company Check:** Please make checks payable to 'Greystone Associates'

**Credit Cards:** We accept MasterCard, Visa and American Express

**Wire Transfers:** See 'Wire Transfers' below for more information

### Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer.

Email to  
[research@greystoneassociates.org](mailto:research@greystoneassociates.org)

Wire Transfers: TD Banknorth  
 300 Franklin Street  
 Manchester, NH 03103  
 (Call for Account Information)

Mailing Address: Greystone Research Associates  
 Client Services  
 P.O. Box 1362  
 Amherst, NH 03031

## Oncology Markets for Tyrosine Kinase Inhibitors

*Therapeutics, Markets, Products, Strategies & Forecasts*

Select	Format	License	Price (U.S. Funds)	Total
<input type="checkbox"/>	PDF	Single User License	\$4,850.00	
<input type="checkbox"/>	PDF	Site License	\$6,500.00	
<input type="checkbox"/>	PDF	Corporate License	\$9,500.00	
<b>Total Payment (U.S. funds)</b>				

Method of Payment:  Company Check        Wire Transfer (International)

Card Number: \_\_\_\_\_ Name on Card \_\_\_\_\_

Expiration Date: \_\_\_\_\_ Card CVV \_\_\_\_\_ Signature \_\_\_\_\_

Billing Information	Shipping Information
Name:	<input type="checkbox"/> Click here if same as Billing Information Name:
Title:	Title:
Company:	Company:
Street Address:	Street Address:
City,State/Province:	City,State/Province:
Country/Postal Code:	Country/Postal Code:
Phone:	Phone:
Fax:	Fax:
Email:	Email: